Showing 2771-2780 of 3315 results for "".
- TearClear Files IND Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solutionhttps://modernod.com/news/tearclear-files-ind-application-to-begin-its-clinical-trial-for-tc-002-latanoprost-ophthalmic-solution/2479495/TearClear has filed an investigational new drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution 0.005%. Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderat
- EyeGate Pharma Completes Target Enrollment in Phase 2 Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammationhttps://modernod.com/news/eyegate-pharma-completes-target-enrollment-in-phase-2-study-to-evaluate-pp-001-for-the-treatment-of-ocular-surface-inflammation/2479490/EyeGate Pharmaceuticals announced that it has completed target enrollment of 21 patients in the phase 2 proof-of-concept (POC) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001
- Azura Ophthalmics Appoints Steven Altschuler, MD, as Chair of the Boardhttps://modernod.com/news/azura-ophthalmics-appoints-steven-altschuler-md-as-chair-of-the-board/2479486/Azura Ophthalmics announced the appointment of Steven M. Altschuler, MD, as chair of its board of directors. Dr. Altschuler brings more than 20 years of experience building, scaling, and leading health care and biotechnology companies. He currently serves as managing director of Healthcare Ventur
- Vision Health Alliance Launches First Consumer Awareness Campaignhttps://modernod.com/news/vision-health-alliance-launches-first-consumer-awareness-campaign/2479484/Vision Health Alliance, The Vision Council’s new consumer education initiative, announced the launch of its first consumer education movement. The “Let’s Be Clear” campaign debuted last week online across multiple digital and social media channels and features direct, to-the-point me
- American Academy of Optometry Foundation Announces Award Recipientshttps://modernod.com/news/american-academy-of-optometry-foundation-announces-award-recipients/2479474/Jonathan D. Lam, MD, OD, was this year’s recipient of the Hopkins Comprehensive Eye Care Award. Dr. Lam is a primary care/ocular disease resident at the Chinle Comprehensive Health Care Facility in Chinle, Arizona. Douglas W. Hopkins, OD, FAAO, was a leader within the Primary Care Section
- Texan Eye Enters Partnership with Comprehensive EyeCare Partnershttps://modernod.com/news/texan-eye-enters-partnership-with-comprehensive-eyecare-partners/2479472/Comprehensive EyeCare Partners (CompEye), a vision care practice management organization, has announced a strategic partnership with Texan Eye, an ophthalmic practice in Central Texas with practices in Austin and Cedar Park. Terms of the deal were not disclosed. Texan Eye, led by su
- Market Scope: Phaco and FLACS Upgrades to Drive Expansion in Cataract Equipment Markethttps://modernod.com/news/market-scope-phaco-and-flacs-upgrades-to-drive-expansion-in-cataract-equipment-market/2479462/A number of market leaders in phaco and femtosecond cataract technology will launch upgraded platforms over the next year, which is expected to increase market penetration for both types of systems and stimulate the replacement of older models. Johnson & Johnson Vision has introduced i
- US Prepares for Wide Rollout of COVID-19 Boosters Next Monthhttps://modernod.com/news/us-prepares-for-wide-rollout-of-covid-19-boosters-next-month/2479458/US officials announced that health agencies in the country are preparing to widely distribute third doses of mRNA COVID-19 vaccines beginning the week of September 20, citing new data that point to waning protection over time. The move was unveiled in a statement signed by health leaders includin
- Oculus Receives FDA Clearance for the Myopia Masterhttps://modernod.com/news/fda-clearance-for-the-new-oculus-myopia-master/2479444/Oculus announced that it has received FDA 510(k) clearance for the Myopia Master, which combines axial length, refraction values, and the central corneal radii measurements. The quick, contactless measurement method for axial length is not influenced by the accommodation status of the eye
- Sydnexis Secures $45 Million Series B Financing to Advance Myopia Drug Candidatehttps://modernod.com/news/sydnexis-secures-45-million-series-b-financing/2479442/Sydnexis announced the completion of a $45 million Series B financing to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children. The financing was led by Visionary Ventures, Blue Stem